Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Exclusion Criteria

• •Those with patient-specific human leukocyte antigen (HLA) loss at relapse;
• •Those with active graft-versus-host disease;
• •Those with severe infection;
• •Those with organ function failure;
• •Those with an Eastern Cooperative Oncology Group (ECOG) score more than 2 points;
• •Those who are allergic to experimental drugs;
• •Those who use other anti-leukemia therapies, such as radiotherapy, cellular immunotherapy, or Chinese medical herbs;
• •Those participate in other clinical trials simultaneously;
• •Those having mental illness or other illnesses that cannot fully comply with treatment or follow-up requirements;
• •Those with extramedullary leukemia;
• •Those with other conditions that researchers evaluate who are not proper to participate in this clinical trial.